MPPW
ELDN icon

Mitchell & Pahl Private Wealth’s Eledon Pharmaceuticals ELDN Stock Holding History

Mitchell & Pahl Private Wealth’s Portfolio ELDN Stock Details ELDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-30,000
Closed -$92.4K – 150
2026
Q1 		$92.4K Buy
+30,000
New +$70.7K 0.04% 145

Other funds holding ELDN

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $747M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $60.8B AUM 42.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CCM
Catalio Capital Management New York $532M AUM 166.55% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ZP
Zimmer Partners New York $4.34B AUM 22.78% 1-Year Est. Return

Mitchell & Pahl Private Wealth's ELDN Position: Q2 2026 in Review

Mitchell & Pahl Private Wealth sold out of Eledon Pharmaceuticals (ELDN) in Q2 2026, closing a stake of 30,000 shares — an estimated $92.4K sold.

Mitchell & Pahl Private Wealth first reported a position in ELDN in Q1 2026 and held it in 1 quarter. The position peaked at $92.4K in Q1 2026. 160 funds tracked by Wall St. Rank hold ELDN as of Q2 2026.

  • Mitchell & Pahl Private Wealth reported no remaining Eledon Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Mitchell & Pahl Private Wealth sold 30,000 Eledon Pharmaceuticals shares in Q2 2026, an estimated $92.4K.
  • Mitchell & Pahl Private Wealth first reported a position in Eledon Pharmaceuticals in Q1 2026 and held it in 1 quarter.
  • Mitchell & Pahl Private Wealth's Eledon Pharmaceuticals position peaked at $92.4K in Q1 2026.
  • 160 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q2 2026.

Based on Mitchell & Pahl Private Wealth's 13F filing for Q2 2026, filed 13 Jul 2026.